NCAM1 and carcinoma: IHC assay of the 11 POLE mutants and 93 POLE wild-type showed that CD8+ T cells, CD4+ T cells, PD-L1+ carcinoma or immune cells, and Foxp3+ T cells had significantly higher IHC scores in POLE mutants compared to POLE wild-type (all P<0.05; Figures 5B, C), while IHC scores of CD56+ NK cells were not statistically differences (P>0.05).